FGF19 and diabetic cardiomyopathy: FGF19 showed better mitochondrial efficiency, which may be related to higher cardiac contractility in the diabetic heart, and the modulation of PGC-1a, responsible for FGF19 activation, may be a therapeutic target for diabetic cardiomyopathy [28].